Loading
In 73 people with breast cancer, a TROP2 PET scan found more cancer deposits than a standard FDG scan, with fewer false alarms, and changed treatment for some.
73 patients with suspected or confirmed breast cancer had both 68Ga-MY6349 and 18F-FDG PET/CT between December 2024 and April 2025. 68Ga-MY6349 found more malignant lesions (564 against 436) and fewer false positives (2 against 40). In 30 initial-staging patients it upgraded stage in 6 (20 per cent) and changed treatment in 4; in 43 restaging patients it changed management in 5 (12 per cent). Overall tumour uptake was higher (median maximum standardised uptake value 5.9 against 4.1, p < 0.001). In three patients with triple-negative breast cancer on sacituzumab tirumotecan, early changes in uptake after two cycles matched the later clinical response; the authors call this preliminary.
A TROP2 scan may help stage breast cancer and, if the early signal holds, judge whether a TROP2 drug is working. It images visible disease, not residual disease after surgery.
Shares 68Ga-MY6349, TROP2 PET, PET (positron emission tomography), TROP2.
Shares 68Ga-MY6349, TROP2 PET, TROP2, Breast cancer (all types).
Shares 68Ga-MY6349, TROP2 PET, PET (positron emission tomography), TROP2.
Shares TROP2 PET, PET (positron emission tomography), TROP2, Triple-negative breast cancer (TNBC).
Shares TROP2 PET, Breast cancer (all types).
Shares TROP2 PET, Sacituzumab tirumotecan, TROP2, Triple-negative breast cancer (TNBC).
Shares TROP2 PET, TROP2, Triple-negative breast cancer (TNBC).
Shares TROP2, Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/